Home>Topics>Stocks>Impax Laboratories

Impax Laboratories IPXL

  1. All
  2. Commentary
  3. Headlines
    1. U.S. FDA raises concerns about Impax's Taiwanese plant

      Headlines

      Tue, 29 Jul 2014

      July 29 (Reuters) - Impax Laboratories Inc said the U.S. Food and Drug Administration issued "certain observations" after an inspection of the company's manufacturing plant in Taiwan.

    2. Impax shares fall after FDA denies approval to Parkinson's drug

      Headlines

      Tue, 22 Jan 2013

      (Reuters) - Shares of Impax Laboratories Inc fell as much as 10 percent on Tuesday, after U.S. health regulators denied approval to the company's Parkinson's drug and asked for a reinspection of its...

    3. Impax gets FDA warning letter, shares fall

      Headlines

      Mon, 6 Jun 2011

      (Reuters) - Impax Laboratories Inc said it received a warning letter from U.S. health regulators on deficient sampling and testing of drugs at its Hayward, California-based plant, sending the...

    4. Prospects Brighten for Medicis' Solodyn

      Commentary

      Fri, 8 Oct 2010

      competition until late 2011, thanks to several deals with Teva TEVA, Sandoz (a unit of Novartis NVS), Mylan MYL, and Impax IPXL . By paying the generic companies to delay competition, Medicis has lengthened the runway for Solodyn. The firm may have bought

    5. Dropping Coverage of Impax

      Commentary

      Mon, 3 Aug 2009

      We are no longer providing equity research on Impax Labs IPXL . We provide broad coverage of more than 1,800 companies across 91 industry groups and adjust our coverage as necessary based on client demand and investor interest.

    6. Medicis under Review

      Commentary

      Wed, 18 Mar 2009

      and expect to make a significant cut to our fair value estimate. Medicis had previously reached an agreement with Impax Labs IPXL (the first to file for approval) to delay the launch of its Solodyn generic until late 2011, but that may not hold if other

    7. Medicis Ends Solodyn Patent Dispute

      Commentary

      Tue, 2 Dec 2008

      Monday that it has settled all outstanding patent disputes over its acne drug Solodyn with generic drug maker Impax Laboratories . Under the agreement, Medicis will pay Impax $40 million up front in return for Impax working in partnership

    8. Medicis' Solodyn in Trouble

      Commentary

      Wed, 23 Jan 2008

      Medicis Pharmaceuticals MRX announced Jan. 15 that it received a formal patent challenge from Impax Laboratories IPXL concerning its Solodyn acne drug. We expect Solodyn to generate sales of about $200 million in 2007, or 44% of Medicis' total

    9. Medicis Receives Patent Challenge

      Commentary

      Tue, 15 Jan 2008

      Medicis Pharmaceuticals MRX announced Tuesday that it has received a formal patent challenge from Impax Laboratories IPXL concerning its Solodyn acne drug. We expect Solodyn to generate sales of about $200 million in 2007, or 44

    10. Endo Receives Patent Challenge

      Commentary

      Thu, 4 Oct 2007

      Endo Pharmaceuticals ENDP announced Wednesday that it has received a formal patent challenge from Impax Laboratories concerning its Opana ER pain drug. We expect Opana ER to generate sales of roughly $100 million in 2007, or about 10% of Endo

    « Prev12Next »
    Content Partners